We collect cookies to analyze our website traffic and performance; we never collect any personal data.Cookies Policy
Accept
Michigan Post
Search
  • Home
  • Trending
  • Michigan
  • World
  • Politics
  • Top Story
  • Business
    • Business
    • Economics
    • Real Estate
    • Startups
    • Autos
    • Crypto & Web 3
  • Tech
  • Lifestyle
    • Lifestyle
    • Food
    • Beauty
    • Art & Books
  • Health
  • Sports
  • Entertainment
  • Education
Reading: The C.D.C. recommends that other vaccines be preferred over J.&J.
Share
Font ResizerAa
Michigan PostMichigan Post
Search
  • Home
  • Trending
  • Michigan
  • World
  • Politics
  • Top Story
  • Business
    • Business
    • Economics
    • Real Estate
    • Startups
    • Autos
    • Crypto & Web 3
  • Tech
  • Lifestyle
    • Lifestyle
    • Food
    • Beauty
    • Art & Books
  • Health
  • Sports
  • Entertainment
  • Education
© 2024 | The Michigan Post | All Rights Reserved.
Michigan Post > Blog > Trending > The C.D.C. recommends that other vaccines be preferred over J.&J.
Trending

The C.D.C. recommends that other vaccines be preferred over J.&J.

By Editorial Board Published December 17, 2021 6 Min Read
Share
The C.D.C. recommends that other vaccines be preferred over J.&J.
16virus briefing cdc jandj facebookJumbo

The Centers for Disease Control and Prevention recommended on Thursday that Covid vaccines other than Johnson & Johnson’s should be preferred, after its advisers cited increasing evidence that the company’s shots can trigger a rare blood clotting disorder now linked to dozens of cases and at least nine deaths in the United States in the past year.

The decision adopted a recommendation by an expert panel that effectively discouraged vaccine providers and adults from using Johnson & Johnson’s shot. New data showed that there was a higher risk for the blood clotting condition than previously known. The risk was greatest among women 30 to 49, estimated at 1 in 100,000 who had received the company’s shot.

Johnson & Johnson’s vaccine is not being removed from the market. It will remain an option for people who are “unable or unwilling” to receive the more popular shots from Moderna or Pfizer-BioNTech, the agency said.

The recommendation is the latest setback for a vaccine that has largely fallen out of favor in the United States. The company’s vaccine has not fulfilled its early promise as a traditional, one-and-done format that would be easy to deploy in more isolated or rural communities, or among people skittish about receiving two doses.

About 16 million people in the United States have received the Johnson & Johnson vaccine as their primary immunization, compared with 73 million fully immunized with Moderna’s vaccine and 114 million with the Pfizer-BioNTech shots. Among Americans who have received a booster, just 1.6 percent chose Johnson & Johnson.

This week, the Food and Drug Administration issued updated guidance on the risks of the blood clotting disorder linked to Johnson & Johnson’s vaccine, but reiterated that the benefits outweighed its risks.

Updated 

Dec. 17, 2021, 10:21 p.m. ET

Dozens of countries have authorized Johnson & Johnson’s vaccine and have been using it as part of their immunization campaigns. But while it remains in high demand in some parts of the world, it has lost popularity in many countries because of safety concerns and its relative lower effectiveness against Covid.

Some governments have already moved to put restrictions on Johnson & Johnson’s shot because of the blood clotting risk. Finland, Denmark and Slovenia stopped using it, and several other nations have ranked it lower for use than Pfizer-BioNTech’s and Moderna’s vaccines. Some countries also have advised doctors to counsel women under 50 of the potential risk.

The C.D.C. panel’s recommendation lands in the middle of a surge in virus cases driven by the Delta coronavirus variant and Omicron, the latest version that has already become dominant in some countries and is spreading fast in Britain and the United States.

The Coronavirus Pandemic: Key Things to Know


Card 1 of 4

Pfizer vaccine in younger children. The company said that a low dose of its coronavirus vaccine did not produce an adequate immune response in 2- to 5-year-olds in ongoing clinical trials. The setback threatens to keep the vaccine from younger children for longer than many had hoped.

U.S. surpasses 800,000 deaths. This past week, Covid deaths in the United States surpassed 800,000 — the highest known number of any country. About 75 percent of those deaths have involved people 65 or older. One in 100 older Americans has died from the virus.

Several laboratory experiments suggest that a single dose of Johnson & Johnson’s shot may offer little defense against infection with Omicron. The company said late last month that it was testing blood samples from clinical trial participants who have received its shot as a booster to see how their vaccine-induced antibodies fare against Omicron.

At Thursday’s meeting of the Advisory Committee on Immunization Practices, C.D.C. officials went into detail on the clotting-related syndrome identified in 54 people in the United States who received the shot before the end of August. Overall, the rate of the condition was 3.8 cases per one million people given the vaccine.

People who received a Johnson & Johnson shot months ago are not thought to be at risk for the clotting condition because the onset of symptoms typically occurred about nine days after vaccination in the diagnosed cases.

An increased risk for the condition has also been linked to the shot from AstraZeneca, which is not authorized in the United States. It has not been linked to the Moderna or Pfizer vaccines.

Evidence has increasingly shown that one dose of Johnson & Johnson’s shot offers much less protection against infection than other vaccines. Federal health officials in October authorized boosters for people who had received a single shot of the company’s vaccine at least two months earlier. They allowed for a “mix and match” approach, allowing people to get a second shot, but of a Pfizer or a Moderna vaccine.

TAGGED:Advisory Committee on Immunization PracticesBlood ClotsCenters for Disease Control and PreventionCoronavirus (2019-nCoV)Food and Drug AdministrationJohnson&JohnsonThe Washington MailVaccination and Immunization
Share This Article
Facebook Twitter Email Copy Link Print

HOT NEWS

Kerry Lutz: Did Martin Armstrong Predict The Nice Decline? | Economics

Kerry Lutz: Did Martin Armstrong Predict The Nice Decline? | Economics

Economics
July 6, 2025
Early miner may very well be behind sudden .6B bitcoin transfer

Early miner may very well be behind sudden $8.6B bitcoin transfer

The bitcoin (BTC) whale chargeable for shifting greater than 80,000 BTC (price over $8.6 billion)…

July 6, 2025
Digital pockets supplier Hyperlayer closes in on £30m funding increase

Digital pockets supplier Hyperlayer closes in on £30m funding increase

A British fintech which counts Customary Life amongst its key shoppers is near finalising one…

July 6, 2025
How Can Refined Language Shifts Unlock Pupil Potential? | Education

How Can Refined Language Shifts Unlock Pupil Potential? | Education

Nudging youngsters to establish as academics distributes authority and experience within the classroom.  When the…

July 6, 2025
Ozzy Osbourne reunites with Black Sabbath for ‘closing bow’ in emotional steel goodbye

Ozzy Osbourne reunites with Black Sabbath for ‘closing bow’ in emotional steel goodbye

Ozzy Osbourne has reunited with Black Sabbath and carried out his closing gig - telling…

July 6, 2025

YOU MAY ALSO LIKE

Streamline, Scale, Succeed: Why Global Enterprises Are Moving to Odoo ERP

Introduction Global businesses face a growing need for centralized, scalable systems. Many still rely on disconnected software tools for operations,…

Tech / ScienceTrending
June 27, 2025

Beloved Children’s Book 𝑻𝒉𝒆 𝑴𝒂𝒑 𝑴𝒚 𝑴𝒐𝒎𝒔 𝑮𝒂𝒗𝒆 𝑴𝒆 Returns to Best-Seller Status Years After Its Release — and Fans Are Begging for More

Years after its quiet but powerful debut, "The Map My Moms Gave Me" has reclaimed the spotlight — this time…

Art & BooksTrending
June 23, 2025

Model With a Mission: In Conversation With Maurice Giovanni

There are models who simply wear clothes—and then there are models who wear the weight of experience, resilience, and purpose…

EntertainmentTrending
June 22, 2025

Building the Future: Abdul Muqtadir Mohammed’s Bold Vision for Autonomous, Intelligent Infrastructure

In an era where artificial intelligence is rapidly transforming industries, Abdul Muqtadir Mohammed stands at the forefront as a true…

BusinessTrending
June 17, 2025

Welcome to Michigan Post, an esteemed publication of the Enspirers News Group. As a beacon of excellence in journalism, Michigan Post is committed to delivering unfiltered and comprehensive news coverage on World News, Politics, Business, Tech, and beyond.

Company

  • About Us
  • Newsroom Policies & Standards
  • Diversity & Inclusion
  • Careers
  • Media & Community Relations
  • Accessibility Statement

Contact Us

  • Contact Us
  • Contact Customer Care
  • Advertise
  • Licensing & Syndication
  • Request a Correction
  • Contact the Newsroom
  • Send a News Tip
  • Report a Vulnerability

Term of Use

  • Digital Products Terms of Sale
  • Terms of Service
  • Privacy Policy
  • Cookie Settings
  • Submissions & Discussion Policy
  • RSS Terms of Service
  • Ad Choices

© 2024 | The Michigan Post | All Rights Reserved

Welcome Back!

Sign in to your account

Lost your password?